Talk:Sitagliptin

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Sitagliptin.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Januvia = Sitagliptin phosphate

Latest comment: 19 years ago2 comments2 people in discussion

According to the FDA release, the drug will be marketed as the phosphate salt, not as the free base. Should the drawing be modified to include thee phosphate? Also, the PubChem code cited is for the free base (which is accurate now), but the one for the phosphate salt is 6451150. I'm not sure what's the common representation in this cases.-- dockingman^Talk 18:19, 18 October 2006 (UTC)Reply

I've responded on your talk. Feel free to leave me a message if you disagree with my edit, by the way! Fvasconcellos 18:35, 18 October 2006 (UTC)Reply

Januvianews

Latest comment: 18 years ago1 comment1 person in discussion

I'm worried about this link: Januvia It appears to be to a marketing web site, but it does not reveal its sponsorship or sources. I moved it to the external links section from the section on who markets sitagliptin. If nobody tells me otherwise, I think I will delete it. Ben 10:17, 13 August 2007 (UTC)Reply

Sitigliptin should not be combined with DPP-1agonists

Latest comment: 14 years ago1 comment1 person in discussion

According to a reliable monograph, Sitiglipin should not be combined with DPP-1 agonists such as exert abide (Byetta, etc.)' since they work on opposite ends of the incretin mechanism, and may result in side effects. I will check this out further. I don't have the references immediately on hand, but will get them. This disagrees with the first paragraph, which implies that it is OK. Does anyone disagree? — Preceding unsigned comment added by 71.92.211.31 (talk) 08:06, 2 July 2012 (UTC)Reply

Januvia

Latest comment: 12 years ago1 comment1 person in discussion

Due to the numerous class action law suits, this drug is worthy of side-stepping until the facts emerge.  — Preceding unsigned comment added by 76.65.103.116 (talk) 02:24, 31 December 2013 (UTC)Reply